Scientific Reports · 2017 · 20 citations · 29 references
Life SciencesEndocrinologyImmunologyCell SignalingSignal TransductionTransplant ImmunologyAllograft RejectionCalcineurin Inhibitor TherapyCalcineurin InhibitorsImmunosuppressive TherapyPeptide DeliveryProtein DeliveryCalcineurin Inhibitor ImmunosuppressionCalcineurin Pathway InhibitionCell Viability AssaysNfat SignalingPeptide Delivery SystemsPeptide-based ImmunomodulationPeptide-mediated DeliveryPhosphatase Inhibition
Calcineurin inhibitors have been used for transplant therapy. However, the inhibition of calcineurin outside the immune system has a number of side effects. We previously developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system. This peptide (11R-VIVIT) selectively interferes with calcineurin-NFAT interaction without affecting the activity of calcineurin phosphatase and provides immunosuppression for fully mismatched islet allografts in mice. However, our recent study showed that 11R-VIVIT affected cell viability in vitro when it was used at higher concentration because of the VIVIT sequence. The aim of this study is to develop a safer NFAT inhibitor (RCAN-11R) that does not affect cell viability, and which is less toxic than calcineurin inhibitors. The minimal sequence of the protein family of regulators of calcineurin (RCAN) that is responsible for the inhibition of calcineurin-NFAT signaling was recently characterized. The peptide could selectively interfere with the calcineurin-NFAT interaction without affecting the activity of calcineurin phosphatase, similar to 11R-VIVIT. RCAN-11R did not affect cell viability when it was used at a higher concentration than the toxic concentration of 11R-VIVIT. RCAN-11R could therefore be useful as a therapeutic agent that is less toxic than current drugs or 11R-VIVIT.
29
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Steven R. Schwarze, Alan L. Ho, Adamina Vocero-Akbani et al. · Science · 1999 · 2.4K citations
International Trial of the Edmonton Protocol for Islet Transplantation
A. M. James Shapiro, Camillo Ricordi, Bernhard J. Hering et al. · New England Journal of Medicine · 2006 · 1.9K citations · Full text
Medicine, Endocrinology, Surgery +16
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Minoru Hojo, Takashi Morimoto, Mary A. Maluccio et al. · Nature · 1999 · 1.2K citations
Medicine, Oncology, Pharmacology +11
Islet isolation assessment in man and large animals
Camillo Ricordi, Derek W. R. Gray, Bernhard J. Hering et al. · Acta Diabetologica · 1990 · 581 citations